Literature DB >> 10382938

Tumour cell detection in G-CSF mobilised stem cell harvests of patients with breast cancer.

W Krüger1, F Tögel, N Kröger, S Rössing, F Gieseking, K Gutensohn, C Lindner, F Jänicke, A R Zander.   

Abstract

Peripheral blood stem cells were mobilised with G-CSF from steady-state haemopoiesis after previous anthracyclin-containing standard dose chemotherapy in patients with high-risk breast cancer. 48 samples were obtained from patients with stage II-III breast cancer and > or = 10 lymph nodes, 15 samples from patients with chemotherapy sensitive metastatic disease, and 13 samples from women with inflammatory breast cancer. 44 samples were first or single leukaphereses and 32 samples were second or third harvests. Aliquots were searched for contaminating tumour cells by immunocytochemistry (IC) and cytokeratin-19 reverse transcriptase polymerase chain reaction rtPCR). The median count of MNCs examined by IC was 2 x 10(6); cDNA prepared from 2 x 10(7) cells was subjected to PCR. Fifty-nine samples were examined by immunocytochemistry, 36 samples by rtPCR, and 19 samples by both techniques. Samples investigated by IC and rtPCR were judged as positive if there was at least one positive test. On the whole, 42/79 (55.3%) of the samples were positive with an insignificant trend to a higher positivity rate in second or subsequent leukaphereses (52.3% vs 59.3%). The median tumour cell load per 10(6) MNCs was low with 0.5 (0-7) cells in all, and a total of 2.2 (0.5-7) cells in positive specimen. Differences in the cancer cell load of first and subsequent leukaphereses and between subgroups of patients were not found. PCR and IC gave consistent results in 63.2%. This phenomenon can be explained by the greater sensitivity of the molecular method and by a Poisson distribution of coharvested tumour cells in samples. Tumour cell contamination in G-CSF mobilised stem cells from patients with breast cancer from steady state haemopoiesis after preceding anthacyclin-containing chemotherapy is frequent, but the tumour cell load is low. To allow a comparison of different studies dealing with cancer cell contamination in stem cells, standardisation of assays is necessary.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10382938     DOI: 10.1007/bf02787354

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  21 in total

Review 1.  Inflammatory breast cancer: the evolution of multimodality treatment strategies.

Authors:  W J Gradishar
Journal:  Semin Surg Oncol       Date:  1996 Sep-Oct

2.  Reverse transcriptase/polymerase chain reaction detection of cytokeratin-19 mRNA in bone marrow and blood of breast cancer patients.

Authors:  W Krüger; C Krzizanowski; M Holweg; M Stockschläder; N Kröger; R Jung; K Mross; W Jonat; A R Zander
Journal:  J Cancer Res Clin Oncol       Date:  1996       Impact factor: 4.553

Review 3.  High dose versus standard dose chemotherapy for the treatment of breast cancer. A review of current concepts.

Authors:  K K Fields; G J Elfenbein; J B Perkins; L C Moscinski
Journal:  Ann N Y Acad Sci       Date:  1995-12-29       Impact factor: 5.691

4.  [Significance of stem cell-supported high-dose chemotherapy in the treatment of gynecological malignancies: indications and current clinical trials in the Federal Republic of Germany].

Authors:  U Nitz; M Frick; A Adomeit; C Jackisch; A Schwenkhagen; V Möbus; H G Bender
Journal:  Zentralbl Gynakol       Date:  1997

5.  High-dose chemotherapy with hematopoietic rescue as primary treatment for metastatic breast cancer: a randomized trial.

Authors:  W R Bezwoda; L Seymour; R D Dansey
Journal:  J Clin Oncol       Date:  1995-10       Impact factor: 44.544

6.  Mobilization of tumor cells and hematopoietic progenitor cells into peripheral blood of patients with solid tumors.

Authors:  W Brugger; K J Bross; M Glatt; F Weber; R Mertelsmann; L Kanz
Journal:  Blood       Date:  1994-02-01       Impact factor: 22.113

7.  Sensitive detection of occult breast cancer by the reverse-transcriptase polymerase chain reaction.

Authors:  Y H Datta; P T Adams; W R Drobyski; S P Ethier; V H Terry; M S Roth
Journal:  J Clin Oncol       Date:  1994-03       Impact factor: 44.544

8.  Comparison of the growth and metastasis of four human intestinal tumor cell line xenografts.

Authors:  S S Joshi; J D Jackson; J G Sharp
Journal:  Tumour Biol       Date:  1989

Review 9.  Multidisciplinary management of advanced primary and metastatic breast cancer.

Authors:  G N Hortobagyi
Journal:  Cancer       Date:  1994-07-01       Impact factor: 6.860

10.  Specificity of reverse transcriptase polymerase chain reaction assays designed for the detection of circulating cancer cells is influenced by cytokines in vivo and in vitro.

Authors:  R Jung; W Krüger; S Hosch; M Holweg; N Kröger; K Gutensohn; C Wagener; M Neumaier; A R Zander
Journal:  Br J Cancer       Date:  1998-11       Impact factor: 7.640

View more
  1 in total

1.  Role of stem cells in cancer therapy and cancer stem cells: a review.

Authors:  Jayesh Sagar; Boussad Chaib; Kevin Sales; Marc Winslet; Alexander Seifalian
Journal:  Cancer Cell Int       Date:  2007-06-04       Impact factor: 5.722

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.